<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39358268</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0485-1439</ISSN><JournalIssue CitedMedium="Print"><Volume>65</Volume><Issue>9</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>[Rinsho ketsueki] The Japanese journal of clinical hematology</Title><ISOAbbreviation>Rinsho Ketsueki</ISOAbbreviation></Journal><ArticleTitle>[Management of HIT/anti-PF4 disorders].</ArticleTitle><Pagination><StartPage>1116</StartPage><EndPage>1124</EndPage><MedlinePgn>1116-1124</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.11406/rinketsu.65.1116</ELocationID><Abstract><AbstractText>Heparin-induced thrombocytopenia (HIT) was widely known as a disease characterized by development of thrombosis with thrombocytopenia after heparin exposure. In addition, vaccine-induced immune thrombotic thrombocytopenia (VITT) has been described as a fatal disease involving simultaneous bleeding and thrombosis after COVID-19 adenovirus vector vaccination. These were caused by HIT antibodies and anti-PF4 antibodies, respectively, but both were autoantibodies that recognized PF4, and were found to have the same pathology with different severities. In recent years, many pathologies in which anti-PF4 antibodies are produced have been reported, and a new concept of anti-PF4 disorder has been proposed. Anti-PF4 disorders are often difficult to identify due to their diverse range of causes, and the prognosis varies greatly depending on whether anti-PF4 antibodies can be measured and early treatment performed after observation of thrombocytopenia of unknown cause or thrombosis at an unusual site. To avoid overlooking anti-PF4 disorders, clinicians should become familiar with the classification of these disorders and accurately select the necessary tests.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yasumoto</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital.</Affiliation></AffiliationInfo></Author></AuthorList><Language>jpn</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Rinsho Ketsueki</MedlineTA><NlmUniqueID>2984782R</NlmUniqueID><ISSNLinking>0485-1439</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>37270-94-3</RegistryNumber><NameOfSubstance UI="D010978">Platelet Factor 4</NameOfSubstance></Chemical><Chemical><RegistryNumber>9005-49-6</RegistryNumber><NameOfSubstance UI="D006493">Heparin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013921" MajorTopicYN="Y">Thrombocytopenia</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010978" MajorTopicYN="Y">Platelet Factor 4</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006493" MajorTopicYN="Y">Heparin</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="N">Thrombosis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anti-PF4 disorder</Keyword><Keyword MajorTopicYN="N">Heparin-induced thrombocytopenia</Keyword><Keyword MajorTopicYN="N">Platelet factor 4</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39358268</ArticleId><ArticleId IdType="doi">10.11406/rinketsu.65.1116</ArticleId></ArticleIdList></PubmedData></PubmedArticle>